Tekla Capital Management LLC Sells 60,264 Shares of AstraZeneca plc (AZN)

Tekla Capital Management LLC cut its holdings in shares of AstraZeneca plc (NYSE:AZN) by 7.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 718,624 shares of the company’s stock after selling 60,264 shares during the period. AstraZeneca comprises about 1.0% of Tekla Capital Management LLC’s portfolio, making the stock its 24th biggest position. Tekla Capital Management LLC’s holdings in AstraZeneca were worth $28,436,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of AZN. Jennison Associates LLC increased its stake in AstraZeneca by 106.2% during the third quarter. Jennison Associates LLC now owns 39,744,304 shares of the company’s stock worth $1,572,682,000 after purchasing an additional 20,470,137 shares during the period. FMR LLC increased its stake in AstraZeneca by 74.5% during the third quarter. FMR LLC now owns 35,325,790 shares of the company’s stock worth $1,397,841,000 after purchasing an additional 15,082,609 shares during the period. Primecap Management Co. CA increased its stake in AstraZeneca by 4.5% during the third quarter. Primecap Management Co. CA now owns 55,399,286 shares of the company’s stock worth $2,192,150,000 after purchasing an additional 2,364,013 shares during the period. Franklin Resources Inc. increased its stake in AstraZeneca by 130.7% during the third quarter. Franklin Resources Inc. now owns 3,557,507 shares of the company’s stock worth $140,770,000 after purchasing an additional 2,015,215 shares during the period. Finally, Northern Trust Corp increased its stake in AstraZeneca by 45.2% during the second quarter. Northern Trust Corp now owns 3,467,814 shares of the company’s stock worth $121,755,000 after purchasing an additional 1,079,790 shares during the period. Institutional investors own 17.18% of the company’s stock.

Shares of AstraZeneca stock traded down $0.12 on Monday, reaching $39.70. 83,342 shares of the company were exchanged, compared to its average volume of 4,621,055. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.66 and a current ratio of 0.86. The company has a market cap of $100.86 billion, a PE ratio of 9.30, a P/E/G ratio of 2.04 and a beta of 0.55. AstraZeneca plc has a 1-year low of $31.99 and a 1-year high of $41.78.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.38. The firm had revenue of $5.34 billion during the quarter, compared to the consensus estimate of $5.26 billion. AstraZeneca had a return on equity of 27.32% and a net margin of 11.29%. The firm’s quarterly revenue was down 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.12 earnings per share. On average, sell-side analysts predict that AstraZeneca plc will post 1.68 earnings per share for the current fiscal year.

A number of analysts have issued reports on the stock. Guggenheim assumed coverage on shares of AstraZeneca in a research note on Monday, October 8th. They set a “buy” rating on the stock. ValuEngine upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Thursday, September 27th. Wolfe Research assumed coverage on shares of AstraZeneca in a research note on Tuesday, October 23rd. They set an “outperform” rating on the stock. Zacks Investment Research lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective on shares of AstraZeneca in a research report on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and a consensus price target of $41.74.

In other AstraZeneca news, major shareholder Plc Astrazeneca purchased 246,666 shares of the stock in a transaction that occurred on Friday, September 28th. The stock was purchased at an average cost of $15.00 per share, with a total value of $3,699,990.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

ILLEGAL ACTIVITY NOTICE: “Tekla Capital Management LLC Sells 60,264 Shares of AstraZeneca plc (AZN)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2018/12/03/tekla-capital-management-llc-sells-60264-shares-of-astrazeneca-plc-azn.html.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit